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Abstract: Interleukin 24 (IL-24) is a tumor-suppressing protein, which inhibits angiogenesis and
induces cancer cell-specific apoptosis. We have shown that IL-24 regulates apoptosis through
phosphorylated eukaryotic initiation factor 2 alpha (eIF2α) during endoplasmic reticulum (ER)
stress in cancer. Although multiple stresses converge on eIF2α phosphorylation, the cellular outcome
is not always the same. In particular, ER stress-induced apoptosis is primarily regulated through
the extent of eIF2α phosphorylation and activating transcription factor 4 (ATF4) action. Our studies
show for the first time that cyclic adenosine monophosphate (cAMP)-dependent protein kinase A
(PKA) activation is required for IL-24-induced cell death in a variety of breast cancer cell lines and
this event increases ATF4 activity. We demonstrate an undocumented role for PKA in regulating
IL-24-induced cell death, whereby PKA stimulates phosphorylation of p38 mitogen-activated protein
kinase and upregulates extrinsic apoptotic factors of the Fas/FasL signaling pathway and death
receptor 4 expression. We also demonstrate that phosphorylation and nuclear import of tumor
suppressor TP53 occurs downstream of IL-24-mediated PKA activation. These discoveries provide
the first mechanistic insights into the function of PKA as a key regulator of the extrinsic pathway, ER
stress, and TP53 activation triggered by IL-24.
Keywords: interleukin 24; melanoma differentiation associated gene 7; protein kinase A; apoptosis;
p53; cytokine; ATF4; extrinsic apoptosis; translation initiation; cancer therapy; gene therapy

1. Introduction
Interleukin-24 (IL-24) is a member of the IL-10 protein family and it displays broad cancer-specific
suppressor effects [1–8]. Notably, clinical and pre-clinical studies have indicated that IL-24 displays
prominent antitumor action [9]. The tumor suppressor activities of IL-24 include the inhibition
of angiogenesis, invasion, and metastasis, sensitization to chemotherapy, and the induction of
cancer-specific apoptosis [1–8]. Given its ubiquitous apoptotic effect on malignant cells, the lack
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of an effect on normal cells, and the absence of significant side effects, IL-24 is an important candidate
for cancer therapy (Reviewed in [8]).
We have shown that overexpression of IL-24 is implicated in endoplasmic reticulum (ER)
stress-mediated apoptosis in cancer cells [10]. We have recently demonstrated that IL-24 activates
protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), one of three canonical ER-stress
response pathways. PERK phosphorylates the alpha subunit of the eukaryotic translation initiation
factor 2 (eIF2a) which inhibits translation initiation while inducing the expression of activating
transcription factor 4 (ATF4) and DNA damage-inducible transcript 3, also known as C/EBP
homologous (GADD153/CHOP) proteins. Thus, the PERK/eIF2α/ATF4/CHOP axis appears to
be essential for the induction of apoptosis by IL-24. Previous studies have shown that protein kinase
A (PKA) can also induce ATF4 expression, leading to apoptosis in human liver carcinoma cells after
treatment with palmitate, a saturated fatty acid, implicated in ER stress [11].
PKA is a serine/threonine kinase that phosphorylates a multitude of proteins in response to
fluctuations in cyclic 30 ,50 -adenosine monophosphate (cAMP) levels. PKA is a holoenzyme consisting
of two catalytic subunits that bind to a dimer of identical regulatory subunits [12]. Under basal
conditions, PKA is inactive, but it can become activated when cAMP levels rise in response to various
stimuli. Once cAMP binds to the PKA regulatory subunits, PKA catalytic subunits are released as
active monomers, which then catalyzes substrate phosphorylation [12]. The cAMP–PKA signaling
integrates downstream pathways to regulate numerous cellular responses, including cell proliferation
and survival, metabolism, cell cycle regulation, cytoskeleton remodeling, and ion channel regulation
(Reviewed in [12]).
In terms of ER stress and ATF4 activation, after the delayed activation of PKA by palmitate, ATF4
interacts with cAMP-responsive element-binding protein 1 (CREB1), a downstream target of PKA,
to bind to the Atf4 promoter, leading to sustained ATF4 protein expression [11]. It is suggested that this
feedback loop involving activated PKA is necessary for the induction of apoptosis via ER-stress and
CREB1 phosphorylation. In addition, it has been shown that inhibition of PKA by dihydrochloride
(H-89) prevents ATF4 and CHOP induction in cells treated with exendin-4, a glucagon-like peptide 1
receptor agonist [13]. Due to effect of PKA on ATF4, a key target in the ER stress pathway, and the
role of PKA as a key growth regulator, we hypothesize that PKA is an upstream mediator of IL-24
killing activity, and that it may regulate several IL-24 downstream signaling pathways, including
ATF4 activation.
In this report, we document for the first time that PKA plays a decisive role in IL-24-mediated
apoptosis. These studies define PKA as a key mediator of IL-24 induction of ATF4 activation,
extrinsic apoptosis, activator of TP53, and p38 mitogen-activated protein kinase (MAPK).
These findings are important in our knowledge of IL-24 as a tumor suppressor protein, as well
as an immunomodulatory cytokine.
2. Results
2.1. IL-24 Regulates the Expression and Phosphorylation of ATF4
We have recently shown that IL-24 inhibits translation initiation by phosphorylating eIF2α during
ER stress [14]. Despite this, it is unclear as to why lL-24 induces its apoptotic effect through ER stress
mechanisms. ER stress activates both pro-survival and pro-apoptotic pathways; however, a particularly
strong or prolonged period of ER stress can overwhelm pro-survival mechanisms, tipping the balance
toward apoptotic pathways, and thus preventing tumor development, growth, and invasion. Multiple
studies show that different environmental and physiological stresses can affect the duration and level of
eIF2α phosphorylation and ATF4 induction and protein interactions, determining cell outcome [15–17].
Therefore, we analyzed whether IL-24 affects the expression of ATF4. We treated MCF-7 human
breast cancer cells with increasing concentrations of adenovirus vector expressing IL-24 (Ad.IL-24)
for 72 h, and analyzed the expression of ATF4 protein by Western blot. As shown in Figure 1, IL-24
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ATF4 expression is induced at the translational level, due to eIF2α phosphorylation and at the
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Next, we explored whether PKA is involved in IL-24-induced apoptosis in breast cancer cells.
To test this hypothesis, we treated several human breast cancer cell lines (MCF-7, T47D, MDA-MB-157,
and MDA-MB-231) with IL-24 in the presence or absence of the specific PKA inhibitors, H-89, and PKI
peptide (sequence: Myr-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH2 ). Cell viability and induction of
apoptosis was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT and
annexin V-fluorescein isothiocyanate/propidium iodide (FITC/PI) assays, respectively. As shown
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IL-24 activates p38 MAPK at threonine 180 and tyrosine 182 in MCF-7 cells. To validate that PKA plays
a role in IL-24-mediated activation of p38 MAPK, we used H-89 in conjunction with IL-24 treatment
and found that the inhibition of PKA prevents the activation of p38 MAPK over 24 h, suggesting that
p38 MAPK signaling pathway is downstream of PKA (Figure 3D).
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Figure 2. IL-24 activates protein kinase A (PKA) in a concentration-dependent manner. (A) MCF-7
cells were treated for 72 h with Ad.IL-24 (25, 50, and 100 pfu per cell) or Ad.vector (100 pfu per cell).
Cells were collected, protein purified, and subjected to Western blot analysis to detect phospho-PKA
substrates, PKA-Cα subunits, and β-actin proteins. (B) MCF-7 cells were treated with Ad.vector (100
pfu/cell) or Ad.IL-24 (25, 50, and 100 pfu per cell) and then assayed for the production of cAMP after
25
50
100
pfu/cell
20 h of treatment. Numbers represent mean cyclic adenosine monophosphate (cAMP) (nM)
Ad.IL-24
concentration after normalization to control. An average of three independent experiments is shown
± SE (n = 9). (C,D) MCF-7 cells were treated for 72 h with Ad.vector (control) or Ad.IL-24 at 100
pfu/cell, andC either untreated or treated withD10 μM H-89 for 72 h. Cells were collected, protein
purified, and subjected to Western blot analysis to detect phospho-PKA substrates, PKA-Cα subunit,
phospho-ATF4, total ATF4, and β-actin.
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[33,34]. Based on these studies, we sought to determine whether IL-24 activates the extrinsic pathway
of apoptosis in MCF-7 breast cancer cells, and whether the IL-24 induction of extrinsic apoptotic
pathway is PKA-dependent. IL-24 infection did indeed increase Fas, FasL, DR4, and FADD levels in
MCF-7 cells within 72 h (Figure 5A). The increase in the expression of the molecular markers
associated
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these results suggest that PKA is necessary for the IL-24-induced extrinsic apoptotic pathway.
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cell) for 72 h. Western blot analysis was performed with antibodies for FasL, Fas, FADD, DR4, and
β-actin. (B) MCF-7 cells were infected with either the Ad.vector (control) or Ad.IL-24 at 100 pfu/cell,
and either untreated or treated with 10 µM H-89 for 72 h. Western blot analysis was performed with
antibodies for FasL, Fas, FADD, DR4, and β-actin.

3. Discussion
Based on the positive results from pre-clinical and Phase I clinical trials [35], IL-24 has been
transitioned into a phase II clinical trial, indicating that it is has the potential to be safe and effective
for cancer gene therapy. We and others have extensively investigated and reported the underlying
apoptotic mechanisms of IL-24 protein treatment and Ad.IL-24 infection in preclinical studies in several
cancer cells, including melanoma, glioblastoma, breast, prostate, lung, colon, liver, and cervical cancer
cells [3–6,10,36–38]. We have shown that Ad.IL-24 and IL-24 protein, produced by Ad.IL-24-infected
cells, display extensive cancer-specific pro-apoptotic activity by stimulating ER stress and ceramide
production in prostate cancer cells with no effect on normal prostate epithelial cells [39]. Secreted
IL-24 protein also generates a strong expression of endogenous IL-24, and subsequent induction
of tumor-specific killing by ER stress activation and reactive oxygen species production [10]. IL-24
also inhibits angiogenesis in human lung tumor cells in vivo, and sensitizes breast cancer cells to
chemotherapy [1,4]. More recently, we have shown that IL-24-triggered-phosphorylation of eIF2α
reduces the availability of the ternary complex in squamous cell carcinoma KLN cells, and preferentially
represses the expression of oncogenic proteins and increases the expression of pro-apoptotic and tumor
suppressor proteins [14].
Although signaling pathways triggered by IL-24 have been the focus of intensive studies for over
20 years, the mechanisms governing cancer-specific apoptosis triggered by IL-24 are still not well
understood. The results presented here identify PKA as a key mediator of cancer-specific killing by
IL-24. For the first time, we show that IL-24 increases intracellular cAMP levels, and activates PKA to
exert its killing effect through the extrinsic apoptotic pathway in MCF-7 breast cancer cells (Figure 5).
IL-24 elevates cAMP levels in a concentration-dependent manner, resulting in PKA activation, and
increases the phosphorylation of PKA substrates (Figure 2A,B) Cell viability and annexin V analysis
shows that cancer cell killing by IL-24 is dependent on PKA, as chemical inhibition of PKA by H-89
abrogates the pro-apoptotic activity of IL-24 on cancer cells (Figure 3A,B). In addition, PKA plays a
role in IL-24-mediated ER stress, as evidenced by activation of ATF4 (Figure 2D)
We observe for the first time that in response to IL-24 treatment, PKA plays a role in the extrinsic
apoptotic pathway. When MCF-7 breast cancer cells are treated with IL-24, key players in the Fas
signaling pathway, such as Fas, FasL, and FADD, are upregulated, supporting previous studies that
IL-24 activates apoptosis extrinsically [33,34,40]. With the addition of the PKA inhibitor H-89, these
apoptotic signaling proteins are downregulated, indicating that the induction of extrinsic apoptotic
pathways by IL-24 is mediated by PKA (Figure 5B).
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In human cancer, tumor suppressor TP53 possesses high mutation rates, and its inhibition or
absence is critical in driving cancer formation and progression. We reveal for the first time that PKA
activation is necessary for IL-24 activation of TP53 at serine 15 (phospho-Ser15 TP53) (Figure 4B).
Phospho-Ser15 TP53 is known to localize to the nucleus to activate cell-cycle arrest and apoptosis
in cancer cells [25–27]. Here, we provide evidence that phospho-Ser15 TP53 localizes to the nucleus
after IL-24 treatment in MCF-7 cells (Figure 4C). This localization to the nucleus is also dependent on
the activity of PKA. Earlier studies have established that IL-24 activates TP53 in MDA-MB-453 breast
cancer cells and HepG2, MHCC97L and Hep3B hepatocellular carcinoma cells [22,23]. As shown in
Figure 2, IL-24 inhibits the growth of different breast cancer cells lines containing wild-type TP53
(MCF-7), mutant TP53 (MDA-MB-231 and T47D), or null TP53 (MDA-MB-157). While we have shown
that IL-24 can induce apoptosis independent of TP53, the molecular mechanisms underlying the
activation of TP53 triggered by IL-24 could be relevant for the development of precise therapeutics that
use IL-24 in combination with compounds that reactivate mutant TP53 to wild-type TP53 to suppress
tumors (Reviewed in [41]). These small-molecule drugs, which have been tested in pre-clinical and
Phase I trials, can specifically target mutant forms of TP53 to reactivate its structural stability, or
restore its transcriptional activity. Future studies examining the synergistic effects of IL-24 and these
compounds can uncover new treatment options for patients that have tumors with mutated TP53
gene profiles.
4. Materials and Methods
4.1. Cells Culture and Reagents
Human breast MCF-7, MDA-MB-231, MDA-MB-157, and T47D cell lines were acquired from
American Type Culture Collection (ATCC), maintained per ATCC protocols and utilized within six
months of thawing. Cell lines were grown in a humidified atmosphere at 37 ◦ C with 5% CO2 , and
culture media was replaced every other day. Dulbecco’s Modified Eagle’s medium (DMEM) was used.
H-89 [N-(2-aminoethyl)-5-isoquinolino-sulfonamide] was purchased from EMD Millipore (Darmstadt,
Germany). PKI Myristoylated Peptide (Sequence: Myr-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH2 )
was purchased from Invitrogen (Camarillo, CA, USA).
4.2. Virus Infection
After attachment within 24 h, cells were infected with the IL-24 expressing replication defective
adenovirus (Ad.IL-24) or the control, a corresponding empty adenovirus vector lacking exogenous genes
(Ad.vector). The adenoviruses were custom made by Vector Biolabs, Inc. (Philadelphia, PA, USA).
4.3. MTT Assays
Prior to treatment, cells were plated at a concentration of 2 × 103 cells/well in 96-well dishes.
Cells were grown in DMEM with 10% FBS (Gibco, Waltham, MA, USA) and attached 12 h prior to
treatment(s). After Ad.IL-24 treatment, cells were treated with inhibitors and media was replaced at
day 3 with fresh inhibitor. After five days of treatment, cell proliferation and viability were determined
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining (Sigma, St. Louis,
MO, USA), as previously described in [42]. Absorbance was measured at 595 nm using Tecan Spark 10
M Microplate Reader (Männedorf, Switzerland) and is proportional the number of living cells present.
4.4. Annexin V Binding Assays
After treatment, cells were detached using trypsin and washed once with complete DMEM
medium and phosphate-buffered saline (PBS). Cells were then re-suspended in 500 µL of binding
buffer containing 2.5 mmol/L CaCl2 , and stained with allophycocyanin-labeled annexin V (Becton
Dickinson Biosciences, Palo Alto, CA, USA) and propidium iodide (PI) at room temperature for 15 min.
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Immediately after staining, flow cytometry was performed. Flow cytometry assays were performed as
previously described [14].
4.5. Western Blot Analysis
Cellular protein was extracted using Pierce IP Lysis Buffer (Thermo Scientific, Rockford, IL,
USA) and a mixture of Halt Protease Inhibitor Cocktail 100X (Thermo Scientific, Rockford, IL, USA)
and Phosphatase Inhibitor Cocktail 100× (Cell Signaling Technology, Danvers, MA, USA). Sixty
micrograms of protein were applied to a 10% SDS/PAGE and transferred to nitrocellulose membranes.
Membranes were incubated with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA)
prior to incubation with polyclonal or monoclonal antibodies to phospho-PKA substrates, PKA-Cα
subunit, FasL, Fas, FADD, DR4, phospho-S15 TP53, total TP53, phospho-p38 MAPK, total p38 MAPK,
phospho-S245 ATF4, total ATF4, BiP, and β-actin overnight at 4 ◦ C. All primary antibodies were
purchased from Cell Signaling Technology (Danvers, MA, USA) with the exception of phospho-S245
ATF4 from Sigma Aldrich (St. Louis, MO, USA). Goat anti-rabbit IgG (H + L) 800 CW, goat anti-rabbit
(680 RD) and/or goat anti-mouse (H + L) secondary antibodies were applied for 1 h at room
temperature (1:25,000, LI-COR) prior to washing with 1× Tris Buffered Saline Tween-20 (TBS-T).
Visualization was carried out with the LI-COR Odyssey CLx imaging system and software.
4.6. cAMP Assay
MCF-7 cells were plated at a concentration of 5 × 103 cells/well in Biocoat Poly-D-Lysine 96-well
dishes. Cells were grown in DMEM with 10% FBS and attached 24 h prior to treatments. Production of
cyclic adenosine monophosphate (cAMP) was determined by the cAMP-GloTM Assay by Promega
(Madison, WI, USA). Luminescence was measured using a Tecan Spark 10M Microplate Reader
(Männedorf, Switzerland).
4.7. Immunofluorescence
Cells were plated onto chamber slides (Falcon; BD Biosciences, San Jose, CA, USA) and
maintained per ATCC protocols. After 24 h of Ad.IL-24 infection and H-89 treatment, cells were
fixed with 2% paraformaldehyde, permeabilized by 0.1% Triton X-100, and then incubated with
phospho-Ser15 TP53 antibody. Incubation buffer was added to chamber slides as negative control.
After 2 washes with wash buffer, chamber slides were then incubated with Alexa Fluor 594 secondary
antibody (Jackson Laboratory, Bar Harbor, ME, USA) for 1 h at room temperature. After rinsing
with wash buffer, chamber slides were coated with 40 ,6-diamidino-2-phenylindole (DAPI) anti-fade
mounting medium (Life Technologies, Grand Island, NY, USA). DAPI-stained nuclei, cells were
assessed on an inverted fluorescent microscope (Nikon EclipseTi, Melville, NY, USA) using 400×
total magnification. Semi-quantitative measurements of the mean FITC intensity of cell nuclei were
taken using NIS Elements software, whereby the average intensity of five cells were taken under each
experimental condition.
4.8. Statistical Analysis
Experiments were performed at least in duplicate or triplicate, and data represent the average
of three independent experiments. Statistical analysis was performed using Student t test. p values
less than or equal to 0.05 were considered significant. Experiments shown are the means of multiple
individual points from multiple experiments (±SEM).
5. Conclusions
Overall, these results demonstrate for the first time that PKA is a key mediator of IL-24-induced
apoptosis in breast cancer cells. Specifically, we reveal that PKA mediates several pathways, including
p38 MAPK, p53, ER stress, and extrinsic apoptosis, which are known to be activated by IL-24 to
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specifically kill cancer cells (Figure 6). The evidence presented here points to PKA as a possible
upstream regulator that potentiates IL-24 killing of cancer cells. Understanding the complexities
of IL-24 induction of apoptosis in cancer cells significantly broadens its potential as an anti-tumor
therapeutic and reveal new combinatorial strategies for targeted cancer therapies.
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